A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer
SIB Swiss Institute of Bioinformatics · Merck Serono (Italy) · +15 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
616
total citations
- FWCI
- 24.64
- Percentile
- 100%
- References
- 38
Citations per year
Authors
20- PFPierre FarmerCorresponding
SIB Swiss Institute of Bioinformatics, Merck Serono (Italy), École Polytechnique Fédérale de Lausanne
- HBHervé Bonnefoi
Institut Bergonié, University of Geneva, European Organisation for Research and Treatment of Cancer, Swiss Group For Clinical Cancer Research
- PAPascale Anderle
Institute of Oncology Research, École Polytechnique Fédérale de Lausanne
- DCDavid Cameron
Western General Hospital, Merck Serono (Italy)
- PWP. Wirapati
SIB Swiss Institute of Bioinformatics
Topics & keywords
Topics
Keywords
- Epirubicin
- Breast cancer
- Chemotherapy
- Oncology
- Gene signature
- Cyclophosphamide
- Stromal cell
- Internal medicine
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.